Pasar al contenido principal

Atherothrombisis in systemic autoimmune diseases: mechanisms and new thereapeutic targets

FJCI-2016-30825

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Juan de la Cierva Formación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms

  • Vázquez Borrego, María del Carmen
  • Fuentes-Fayos, Antonio C.
  • Herrera-Martínez, Aura D.
  • L-López, Fernando
  • Ibáñez-Costa, Alejandro
  • Moreno Moreno, Paloma
  • Alhambra Expósito, María Rosa
  • Barrera-Martín, Ana
  • Blanco-Acevedo, Cristóbal
  • Dios, Elena
  • Venegas-Moreno, Eva
  • Solivera, Juan
  • Gahete Ortiz, Manuel D.
  • Soto-Moreno, Alfonso
  • Gálvez-Moreno, M. Ángeles
  • Castaño, Justo P.
  • Luque, Raúl M.
Context: Pituitary neuroendocrine tumors (PitNETs) are a commonly underestimated pathology in terms of incidence and associated morbimortality. Currently, an appreciable subset of patients are resistant or poorly responsive to the main current medical treatments [i.e., synthetic somatostatin analogs (SSAs) and dopamine agonists]. Thus, development and optimization of novel and available medical therapies is necessary. Biguanides (metformin, buformin, and phenformin) are antidiabetic drugs that exert antitumoral actions in several tumor types, but their pharmacological effects on PitNETs are poorly known. Objective: We aimed to explore the direct effects of biguanides on key functions (cell viability, hormone release, apoptosis, and signaling pathways) in primary cell cultures from human PitNETs and cell lines. Additionally, we evaluated the effect of combined metformin with SSAs on cell viability and hormone secretion. Design: A total of 13 corticotropinomas, 13 somatotropinomas, 13 nonfunctioning PitNETs, 3 prolactinomas, and 2 tumoral pituitary cell lines (AtT-20 and GH3) were used to evaluate the direct effects of biguanides on cell viability, hormone release, apoptosis, and signaling pathways. Results: Biguanides reduced cell viability in all PitNETs and cell lines (with phenformin being the most effective biguanide) and increased apoptosis in somatotropinomas. Moreover, buformin and phenformin, but not metformin, reduced hormone secretion in a cell type–specific manner. Combination metformin/SSA therapy did not increase SSA monotherapy effectiveness. Effects of biguanides on PitNETs could involve the modulation of AMP-activated protein kinase–dependent ([Ca21]i, PI3K/Akt) and independent (MAPK) mechanisms. Conclusion: Altogether, our data unveil clear antitumoral effects of biguanides on PitNET cells, opening avenues to explore their potential as drugs to treat these pathologies. (J Clin Endocrinol Metab 104: 3501–3513, 2019)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms

  • Vázquez-Borrego, Mari C.
  • Fuentes-Fayos, Antonio C.
  • Herrera-Martínez, Aura D.
  • López, Fernando L.
  • Ibáñez-Costa, Alejandro
  • Moreno-Moreno, Paloma
  • Alhambra-Expósito, María R.
  • Barrera-Martín, Ana
  • Blanco-Acevedo, Cristóbal
  • Dios Fuentes, Elena
  • Venegas Moreno, Eva
  • Solivera, Juan
  • Gahete, Manuel D.
  • Soto-Moreno, Alfonso
  • Gálvez-Moreno, María Ángeles
  • Castaño, Justo P.
  • Luque, Raúl M.
[Context] Pituitary neuroendocrine tumors (PitNETs) are a commonly underestimated pathology in terms of incidence and associated morbimortality. Currently, an appreciable subset of patients are resistant or poorly responsive to the main current medical treatments [i.e., synthetic somatostatin analogs (SSAs) and dopamine agonists]. Thus, development and optimization of novel and available medical therapies is necessary. Biguanides (metformin, buformin, and phenformin) are antidiabetic drugs that exert antitumoral actions in several tumor types, but their pharmacological effects on PitNETs are poorly known., [Objective] We aimed to explore the direct effects of biguanides on key functions (cell viability, hormone release, apoptosis, and signaling pathways) in primary cell cultures from human PitNETs and cell lines. Additionally, we evaluated the effect of combined metformin with SSAs on cell viability and hormone secretion., [Design] A total of 13 corticotropinomas, 13 somatotropinomas, 13 nonfunctioning PitNETs, 3 prolactinomas, and 2 tumoral pituitary cell lines (AtT-20 and GH3) were used to evaluate the direct effects of biguanides on cell viability, hormone release, apoptosis, and signaling pathways., [Results] Biguanides reduced cell viability in all PitNETs and cell lines (with phenformin being the most effective biguanide) and increased apoptosis in somatotropinomas. Moreover, buformin and phenformin, but not metformin, reduced hormone secretion in a cell type–specific manner. Combination metformin/SSA therapy did not increase SSA monotherapy effectiveness. Effects of biguanides on PitNETs could involve the modulation of AMP-activated protein kinase–dependent ([Ca2+]i, PI3K/Akt) and independent (MAPK) mechanisms., [Conclusion] Altogether, our data unveil clear antitumoral effects of biguanides on PitNET cells, opening avenues to explore their potential as drugs to treat these pathologies., This work has been funded by the following grants: Junta de Andalucía (CTS-1406 to R.M.L., BIO-0139 to J.P.C.), Ministerio de Ciencia, Innovación y Universidades (BFU2016-80360-R to J.P.C., FJCI-2016-30825 to A.I.C.), and Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, “Investing in Your Future”: PI16/00264 to R.M.L., CP15/00156 to M.D.G., and CIBERobn). CIBER is an initiative of Instituto de Salud Carlos III., Peer reviewed